Athersys

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. The Company is engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of the proprietary technologies, Athersys has established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

Revenue(Q1, 2017)

$1.5 M

Market capitalization(2017-08-22)

$182.3 M

Patent Applications (FY, 2016)

170

Company Growth (employees)

Type

Public

Cleveland, US

Founded

1995

Size (employees)

60 (est)

Website

athersys.com

Athersys was founded in 1995 and is headquartered in Cleveland, US

Key People at Athersys

Gil Van Bokkelen

Chairman & CEO

William Lehmann Jr

President, COO

John Harrington

Executive Vice President and Chief Scientific Officer

Laura Campbell

Controller

Manal Morsy

Vice President, Global Regulatory Affairs

Athersys Office Locations

Athersys has offices in Cleveland and Canton

Cleveland, US (HQ)

3201 Carnegie Ave

Canton, US

250 Royall St

Athersys Data and Metrics

Athersys Financial Metrics

Athersys's revenue was reported to be $1.5 m in Q1, 2017

Summary

USD

Athersys's current market capitalization is $182.3 m.

Source: SEC Filings

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	2.4 m	1.6 m	11.9 m	17.3 m
Revenue growth, %		(33%)	636%	45%
EBIT	(24.5 m)	(29 m)	(17.2 m)	(15 m)
EBIT margin, %	(1003%)	(1788%)	(144%)	(87%)
Pre tax profit	(30.7 m)	(22.3 m)	(16.5 m)	(15.4 m)
Net Income	(30.7 m)	(22.1 m)	(16.4 m)	(15.3 m)

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Revenue	388 k	293 k	731 k	216 k	396 k	15.5 m	595 k	311 k	1.5 m
R&D expense	5.8 m	5.8 m	5.7 m	5.3 m	5.1 m	6.7 m	5.8 m	5.3 m	5.6 m
General and administrative expense	1.8 m	1.7 m	1.9 m	1.9 m	1.9 m	2 m	2 m	1.8 m	2.1 m
Operating expense total	7.6 m	7.5 m	7.6 m	7.2 m	7 m	8.7 m	7.8 m	7.1 m	7.7 m
EBIT	(7.3 m)	(7.3 m)	(6.9 m)	(7 m)	(6.7 m)	6.7 m	(7.3 m)	(6.2 m)	(6.4 m)
EBIT margin, %	(1878%)	(2481%)	(943%)	(3256%)	(1692%)	43%	(1224%)	(1998%)	(435%)
Pre tax profit						4.7 m	(7 m)	(6 m)
Income tax expense						9 k	13 k	12 k	13 k

Source: SEC Filings

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	31.9 m	26.1 m	23 m	14.8 m
Accounts Receivable	520 k	694 k	361 k	598 k
Current Assets	32.9 m	27.2 m	23.8 m	16.3 m
Total Assets	34.2 m	28.7 m	25.1 m	19.1 m
Accounts Payable	2.2 m	2.8 m	2.7 m	4.8 m
Total Debt	176 k	183 k	190 k
Current Liabilities	4.4 m	4.7 m	4.8 m	6.9 m
Additional Paid-in Capital	284.3 m	307.3 m	322.6 m	329.4 m
Retained Earnings	(264.4 m)	(286.5 m)	(302.9 m)	(318.3 m)
Total Equity	19.8 m	20.9 m	19.7 m	11.2 m
Debt to Equity Ratio	0 x	0 x	0 x
Debt to Assets Ratio	0 x	0 x	0 x
Financial Leverage	1.7 x	1.4 x	1.3 x	1.7 x

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Cash	38.8 m	32.4 m	35.5 m	32.3 m	28.5 m	30.4 m	13.8 m	8.3 m	31.9 m
Accounts Receivable	715 k	665 k						298 k	1.8 m
Current Assets	39.8 m	33.4 m	38.7 m	35.1 m	29.2 m	31.5 m	25.7 m	20.5 m	34.9 m
Total Assets	41.1 m	34.8 m	40.2 m	36.5 m	30.6 m	33 m	27.9 m	23.3 m	37.6 m
Accounts Payable	2.8 m	2.9 m	2.7 m	2.3 m	2.6 m	3.3 m	4.2 m	3.6 m	6.6 m
Current Liabilities	4.5 m	4.8 m	14.2 m	14 m	14.3 m	4.7 m	5.7 m	5.2 m	8.4 m
Additional Paid-in Capital	306 m	306.7 m	317.9 m	321.3 m	322 m	323.5 m	324.8 m	327.1 m	353.1 m
Retained Earnings	(275.2 m)	(280 m)	(299 m)	(300 m)	(306.5 m)	(298.2 m)	(305.1 m)	(311.2 m)	(324 m)
Total Equity	30.9 m	26.8 m	19 m	21.4 m	15.5 m	25.4 m	19.8 m	16 m	29.2 m
Financial Leverage	1.3 x	1.3 x	2.1 x	1.7 x	2 x	1.3 x	1.4 x	1.5 x	1.3 x

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	(30.7 m)	(22.1 m)	(16.4 m)	(15.3 m)
Depreciation and Amortization	346 k	360 k	267 k	382 k
Accounts Receivable	(30 k)	(174 k)	333 k	(237 k)
Accounts Payable	(196 k)	335 k	(296 k)	2.4 m
Cash From Operating Activities	(22.8 m)	(25.8 m)	(13.8 m)	(10.9 m)
Cash From Investing Activities	(385 k)	(297 k)	(132 k)	(1.1 m)
Cash From Financing Activities	29.6 m	20.3 m	10.8 m	3.7 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Depreciation and Amortization	93 k	91 k	70 k	65 k	66 k	68 k	67 k	114 k	164 k
Accounts Receivable	715 k	665 k						298 k	1.8 m
Accounts Payable	2.8 m	2.9 m	2.7 m	2.3 m	2.6 m	3.3 m	4.2 m	3.6 m	6.6 m

Ratios

USD	Y, 2017
Revenue/Employee	24.5 k
Financial Leverage	1.3 x

Athersys Operating Metrics

Athersys's Patent Applications was reported to be 170 in FY, 2016

	FY, 2016
Patents Issued	200
Patents (US)	21
Patent Applications	170

Source: SEC Filings

Athersys Market Value History

Market Position of Athersys

Competitors

Biogen

Health - Public

Ironwood Pharmaceuticals

Health - Public

Alimera Sciences

Health - Public

Vertex Pharmaceuticals

Health - Public

Compare competitors

Athersys

Company Growth (employees)

Key People at Athersys

Gil Van Bokkelen

William Lehmann Jr

John Harrington

Laura Campbell

Manal Morsy

Athersys Office Locations

Athersys Data and Metrics

Athersys Financial Metrics

Summary

Revenue (Q1, 2017)

EBIT (Q1, 2017)

Market capitalization (22-Aug-2017)

Cash (31-Mar-2017)

Income Statement

Revenue

Revenue growth, %

EBIT

EBIT margin, %

Pre tax profit

Net Income

Revenue

R&D expense

General and administrative expense

Operating expense total

EBIT

EBIT margin, %

Pre tax profit

Income tax expense

Balance Sheet

Cash

Accounts Receivable

Current Assets

Total Assets

Accounts Payable

Total Debt

Current Liabilities

Additional Paid-in Capital

Retained Earnings

Total Equity

Debt to Equity Ratio

Debt to Assets Ratio

Financial Leverage

Cash

Accounts Receivable

Current Assets

Total Assets

Accounts Payable

Current Liabilities

Additional Paid-in Capital

Retained Earnings

Total Equity

Financial Leverage

Cash Flow

Net Income

Depreciation and Amortization

Accounts Receivable

Accounts Payable

Cash From Operating Activities

Cash From Investing Activities

Cash From Financing Activities

Depreciation and Amortization

Accounts Receivable

Accounts Payable

Ratios

Revenue/Employee

Financial Leverage

Athersys Operating Metrics

Patents Issued

Patents (US)

Patent Applications

Athersys Market Value History

Market Position of Athersys

Competitors

Traffic Overview of Athersys

Athersys Online and Social Media Presence

Athersys Company Life and Culture

You may also be interested in